{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:38:06Z","timestamp":1782970686091,"version":"3.54.5"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Cushing\u2019s disease (CD) is associated with high rates of depression and anxiety that often persist despite biochemical remission, yet the underlying mechanisms remain unclear. This study aims to characterize circulating neurosteroid (NS) profiles in CD and examine their associations with psychological symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and methods<\/jats:title>\n                    <jats:p>This is a cross-sectional study of 37 patients with CD (22 active, 15 remission) and 21 nonfunctioning pituitary adenoma (NFA) controls. NS levels were quantified by mass spectrometry; psychological symptoms were assessed using the 21-item Depression Anxiety Stress Scale (DASS-21). Discriminatory NS were identified by partial least squares discriminant analysis (PLS-DA), with a variable importance in projection (VIP) score &amp;gt; 1.0 used as the selection threshold.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients with CD exhibited higher depression (14 vs. 7.5,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.03) and stress scores (17 vs. 8.5,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.03) than NFA. PLS-DA identified five discriminatory NS: 4-androstenedione (VIP = 2.0), 11-deoxycorticosterone (DOC) (VIP\u00a0=\u00a01.8), 7-OH-pregnenolone (VIP = 1.8), corticosterone (VIP = 1.7), and androsterone (VIP = 1.1); the first four were elevated, and androsterone decreased in CD. Despite biochemical remission, most NS alterations persisted, with 7-OH-pregnenolone paradoxically increasing further (121 vs. 22.5 ng\/mL,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.008). Mood symptoms did not correlate with cortisol, adrenocorticotropic hormone (ACTH), or urinary free cortisol (UFC). However, dehydroepiandrosterone (DHEA) correlated positively with depression (\n                      <jats:italic>r<\/jats:italic>\n                      \u00a0=\u00a00.4,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.02) and stress (\n                      <jats:italic>r<\/jats:italic>\n                      \u00a0=\u00a00.4,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.02), whereas allopregnanolone correlated negatively with depression (\n                      <jats:italic>r<\/jats:italic>\n                      = \u22120.4,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.03) and stress (\n                      <jats:italic>r<\/jats:italic>\n                      = \u22120.4,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.04). Among discriminatory NS, only 7-OH-pregnenolone correlated with stress (\n                      <jats:italic>r<\/jats:italic>\n                      \u00a0=\u00a00.3,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.04). These NS\u2013mood associations were absent in NFA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CD is characterized by a distinct and persistent steroid signature that persists beyond biochemical remission, reflecting hypercortisolism-driven epigenetic remodeling of steroidogenic pathways. The dissociation between ACTH-driven steroid alterations and mood-associated NS suggests that cortisol reduction alone may inadequately address psychiatric symptoms, warranting investigation of NS-targeted therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1829888","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:25:25Z","timestamp":1782966325000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Steroid alterations in Cushing\u2019s disease persist after remission: ACTH-driven steroid changes dissociate from mood-regulatory neurosteroids"],"prefix":"10.3389","volume":"17","author":[{"given":"Sebnem","family":"Burhan","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, University of Health Sciences, Basaksehir Cam and Sakura City Hospital","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebubekir","family":"Akpinar","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Health Sciences, Basaksehir Cam and Sakura City Hospital","place":["Istanbul, T\u00fcrkiye"]},{"name":"University of Health Sciences, Pituitary Disorders Application and Research Center (HATMER)","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevim","family":"Eyupoglu","sequence":"additional","affiliation":[{"name":"Department of Psychology, Atlas University","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayhan","family":"Bingol","sequence":"additional","affiliation":[{"name":"Department of Psychology, Davranis Degisim Akademia","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Korkmaz Yilmaz","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, University of Health Sciences, Basaksehir Cam and Sakura City Hospital","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aslihan","family":"Pekmezci","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, University of Health Sciences, Basaksehir Cam and Sakura City Hospital","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebru","family":"Turgal","sequence":"additional","affiliation":[{"name":"Strathclyde Institute of Pharmacy and Biomedical Sciences","place":["Glasgow, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huseyin Sehit","family":"Burhan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Health Sciences, Basaksehir Cam and Sakura City Hospital","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutlu","family":"Niyazoglu","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, University of Health Sciences, Basaksehir Cam and Sakura City Hospital","place":["Istanbul, T\u00fcrkiye"]},{"name":"University of Health Sciences, Pituitary Disorders Application and Research Center (HATMER)","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra Suheda","family":"Hatipoglu","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, University of Health Sciences, Basaksehir Cam and Sakura City Hospital","place":["Istanbul, T\u00fcrkiye"]},{"name":"University of Health Sciences, Pituitary Disorders Application and Research Center (HATMER)","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200115050-00003","article-title":"Psychiatric disorders associated with Cushing\u2019s syndrome: epidemiology, pathophysiology and treatment","volume":"15","author":"Sonino","year":"2001","journal-title":"CNS Drugs"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab079","article-title":"Psychotropic drugs in patients with Cushing\u2019s disease before diagnosis and at long-term follow-up: a nationwide study","volume":"106","author":"Bengtsson","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf598","article-title":"Prospective assessment of mood and quality of life in Cushing syndrome before and after biochemical control","volume":"111","author":"Theodorou","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1042\/ebc20200043","article-title":"Biosynthesis and signalling functions of central and peripheral nervous system neurosteroids in health and disease","volume":"64","author":"Lloyd-Evans","year":"2020","journal-title":"Essays Biochem"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/jne.12351","article-title":"Neurosteroidogenesis today: novel targets for neuroactive steroid synthesis and action and their relevance for translational research","volume":"28","author":"Porcu","year":"2016","journal-title":"J Neuroendocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054758","article-title":"Gender and neurosteroids: implications for brain function, neuroplasticity and rehabilitation","volume":"24","author":"Raciti","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041758","article-title":"Neurosteroids and neurotrophic factors: what is their promise as biomarkers for major depression and PTSD","volume":"22","author":"Almeida","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2019.00083","article-title":"Neuroactive steroids and GABAergic involvement in the neuroendocrine dysfunction associated with major depressive disorder and postpartum depression","volume":"13","author":"Maguire","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pneurobio.2013.09.003","article-title":"The role of allopregnanolone in depression and anxiety","volume":"113","author":"Sch\u00fcle","year":"2014","journal-title":"Prog Neurobiol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ynstr.2020.100218","article-title":"The role of allopregnanolone in depressive-like behaviors: Focus on neurotrophic proteins","volume":"12","author":"Almeida","year":"2020","journal-title":"Neurobiol Stress"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.22399","article-title":"The neurosteroids allopregnanolone and dehydroepiandrosterone modulate resting\u2010state amygdala connectivity","volume":"35","author":"Sripada","year":"2014","journal-title":"Hum Brain Mapp"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019873320","article-title":"Brexanolone (Zulresso): finally, an FDA-approved treatment for postpartum depression","volume":"54","author":"Powell","year":"2020","journal-title":"Ann Pharmacother"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105327","article-title":"Neurosteroid influence on affective tone","volume":"152","author":"Walton","year":"2023","journal-title":"Neurosci Biobehav Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2012.10.005","article-title":"Neurosteroids, stress and depression: potential therapeutic opportunities","volume":"37","author":"Zorumski","year":"2013","journal-title":"Neurosci Biobehav Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13142","article-title":"Long\u2010term effects of glucocorticoid excess on the brain","volume":"34","author":"Dekkers","year":"2022","journal-title":"J Neuroendocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1163482","article-title":"Functional brain alterations in Cushing\u2019s syndrome","volume":"14","author":"Papakokkinou","year":"2023","journal-title":"Front Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13056","article-title":"Psychiatric and neurocognitive consequences of endogenous hypercortisolism","volume":"288","author":"Piasecka","year":"2020","journal-title":"J Intern Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2006.05232.x","article-title":"Chronic treatment with high doses of corticosterone decreases cytoskeletal proteins in the rat hippocampus","volume":"24","author":"Cereseto","year":"2006","journal-title":"Eur J Neurosci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/0005-7967(94)00075-u","article-title":"The structure of negative emotional states: Comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories","volume":"33","author":"Lovibond","year":"1995","journal-title":"Behav Res Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/03069885.2018.1442558","article-title":"Psychometric properties of the Turkish version of the Depression Anxiety Stress Scale-21 (DASS-21)","volume":"46","author":"Y\u0131ld\u0131r\u0131m","year":"2018","journal-title":"Br J Guid Couns"},{"key":"B21","doi-asserted-by":"publisher","first-page":"106119","DOI":"10.1016\/j.neubiorev.2025.106119","article-title":"New directions in neurosteroid therapeutics in neuropsychiatry","volume":"172","author":"Zorumski","year":"2025","journal-title":"Neurosci Biobehav Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.14615","article-title":"Sex, stress and steroids","volume":"52","author":"Sze","year":"2020","journal-title":"Eur J Neurosci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2826.2002.00798.x","article-title":"Functional cross\u2010talk between the hypothalamic\u2010pituitary\u2010gonadal and\u2010adrenal axes","volume":"14","author":"Viau","year":"2002","journal-title":"J Neuroendocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02349","article-title":"Plasma steroid profiles in subclinical compared with overt adrenal Cushing syndrome","volume":"104","author":"Masjkur","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ygcen.2017.09.014","article-title":"7\u03b1-Hydroxypregnenolone regulating locomotor behavior identified in the brain and pineal gland across vertebrates","volume":"265","author":"Tsutsui","year":"2018","journal-title":"Gen Comp Endocrinol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1210\/en.2011-1422","article-title":"Acute stress increases the synthesis of 7\u03b1-hydroxypregnenolone, a new key neurosteroid stimulating locomotor activity, through corticosterone action in newts","volume":"153","author":"Haraguchi","year":"2012","journal-title":"Endocrinology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00043","article-title":"Effects of chronic ACTH excess on human adrenal cortex","volume":"8","author":"Bertagna","year":"2017","journal-title":"Front Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae151","article-title":"Epigenetic mechanisms modulated by glucocorticoids with a focus on cushing syndrome","volume":"109","author":"Paes","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0735-z","article-title":"Psychiatric symptoms in patients with Cushing\u2019s syndrome: prevalence, diagnosis and management","volume":"77","author":"Santos","year":"2017","journal-title":"Drugs"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac269","article-title":"Consequences of Cushing\u2019s syndrome: health versus personal costs","volume":"107","author":"Webb","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing\u2019s syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0636-7","article-title":"Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies","volume":"18","author":"Andela","year":"2015","journal-title":"Pituitary"},{"key":"B33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.biopsych.2020.02.966","article-title":"Cortical thickness abnormalities in long-term remitted Cushing\u2019s disease","volume":"10","author":"Bauduin","year":"2020","journal-title":"Transl Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1375","article-title":"Quality of life in patients after long-term biochemical cure of Cushing\u2019s disease","volume":"90","author":"Van Aken","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2022.101033","article-title":"Structural and functional brain alterations in Cushing\u2019s disease: A narrative review","volume":"67","author":"Liu","year":"2022","journal-title":"Front Neuroendocrinol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/89.7.543","article-title":"Psychiatric aspects of Cushing\u2019s syndrome","volume":"89","author":"Kelly","year":"1996","journal-title":"Qjm Int J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1159\/000182736","article-title":"Course of depression in Cushing\u2019s syndrome: response to treatment and comparison with Graves\u2019 disease","volume":"39","author":"Sonino","year":"1993","journal-title":"Horm Res Paediatr"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-1083-6","article-title":"Reduced DNA methylation of FKBP5 in Cushing\u2019s syndrome","volume":"54","author":"Resmini","year":"2016","journal-title":"Endocrine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178568","article-title":"The sex hormone precursors dehydroepiandrosterone (DHEA) and its sulfate ester form (DHEAS): molecular mechanisms and actions on human body","volume":"26","author":"Lin","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.26516","article-title":"Dehydroepiandrosterone mediates associations between trauma\u2010related symptoms and anterior pituitary volume in children and adolescents","volume":"44","author":"Picci","year":"2023","journal-title":"Hum Brain Mapp"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.07.026","article-title":"Testosterone, estradiol, DHEA and cortisol in relation to anxiety and depression scores in adolescents","volume":"294","author":"Chronister","year":"2021","journal-title":"J Affect Disord"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2012.09.004","article-title":"Serum dehydroepiandrosterone (DHEA) and DHEA-sulfate (S) levels in medicated patients with major depressive disorder compared with controls","volume":"146","author":"Kurita","year":"2013","journal-title":"J Affect Disord"},{"key":"B43","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1186\/s12885-024-12195-9","article-title":"The associates of anxiety among lung cancer patients: Dehydroepiandrosterone (DHEA) as a potential biomarker","volume":"24","author":"Wu","year":"2024","journal-title":"BMC Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105682","article-title":"Allopregnanolone in mood disorders: Mechanism and therapeutic development","volume":"169","author":"Chen","year":"2021","journal-title":"Pharmacol Res"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1829888\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:25:26Z","timestamp":1782966326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1829888\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":44,"alternative-id":["10.3389\/fendo.2026.1829888"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1829888","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"article-number":"1829888"}}